Mitsubishi Tanabe Pharma Corporation

Osamu Sakurai

Kosuke Yasuda

Hiroshi Miyazaki

Norimitsu Hayashi

Iwao Takamuro

Hiroaki Sawamoto

Kunio Saruta

Tetsuya Yanagida

Yutaka Hisada

Ritsuo Imashiro

Kenji Morokuma

Hiroaki Shitama

Junko Tsubakimoto

Hidekazu Tsujishima

Junko Okabe

Takashi Goi

Eri Ooboki

Eri Oboki

The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CRor nitrogen atom; Ris hydrogen and the like; Ris alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.

Aromatic heterocyclic compound

This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof. 

Continuous arycyclic compound

An arylalkylamine compound is represented by the following formula [I-e] or a pharmaceutically acceptable salt thereof. 

Arylalkylamine compound and process for preparing the same

The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc.  The symbols in the formula represent the following meanings:

The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc. 

Growing community of inventors

Osaka, Japan

Osamu Sakurai